4 days ago · Epitopea is a transatlantic cancer immunotherapeutics company based in Montreal, Canada and Cambridge, UK.

In addition to its top-tier international investor syndicate, Epitopea is also proud to be supported by a strong network of contract partners from the public and private sector, that are providing Epitopea with R&D related support.

Given these proprietary Cryptigen TM TSAs are uniquely expressed and presented by cancer cells and are broadly shared across patients with the same tumor, they provide a tumor-specific targeted rationale for the development of RNA-based immunotherapies that are shared across broad patient populations. Cryptigen TM TSAs are hidden antigens that have largely escaped detection, but their ...

CAMBRIDGE, UK and MONTREAL, CANADA, 7 February 2025 — Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, […] Read More Epitopea and Genevant Sciences …

Apr 25, 2022 · Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication.

Dec 19, 2024 · Under the terms of the agreement, Genevant granted to Epitopea a nonexclusive worldwide license to certain Genevant LNP technology to develop RNA-based immunotherapies targeting Epitopea’s Cryptigen™ TSAs in an undisclosed oncology indication.

Epitopea Announces License and Research Collaboration Agreement with MSD to Identify CryptigenTM Tumor-Specific Antigens

At Epitopea, we foster a culture of excellence, collaboration, equality and diversity, offering a comprehensive benefits and lifestyle package. Email us at [email protected] with your CV and a cover letter telling us how you can make a difference at Epitopea.

Oct 24, 2024 · CAMBRIDGE, UK and MONTREAL, CANADA, 24 October 2024 - Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, announces the closing of a USD $31 million pre-Series A financing.

Sep 26, 2024 · Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped tumor-specific antigens, which are known as Cryptigen TM TSAs, that are broadly shared across multiple patients with the same tumor type.